Trial Profile
A Randomised, Double-blind, Two-way Crossover Study to Investigate the Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary) ; Salbutamol sulfate
- Indications Asthma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 06 Mar 2017 Primary endpoint (Mean growth rate in lower leg growth) has been met as per results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 08 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.